New CEO takes over
Contract Research Organization Julius Clinical (NL) appointed Bassem Saleh as its new Chief Executive Officer. His predecessor, Martijn Wallert, will become an advisor to the Executive Board.
Netherlands-headquartered Contract Research Organization Julius Clinical appointed Bassem Saleh as its new Chief Executive Officer. Martijn Wallert, who has led Julius Clinical as CEO since June 2021, will continue supporting the company in his new role as Board Advisor.
Bassem brings a wealth of leadership experience from his time at both large and mid-sized CRO’s, most recently as CEO of TFS HealthScience. Throughout his career, he has successfully led organizations through expansive international growth, mergers and acquisitions and the development of specialized therapeutic business units in CNS, Dermatology, Ophthalmology and Oncology. His expertise in structuring operations around specific therapeutic areas aligns closely with Julius Clinical’s ambitious growth strategy in CNS, Cardiometabolic and rare diseases.
Marquard - Ruhr University Bochum
Menarini Group
Astoriom